New York State Medicaid Coverage of Tumor Treatment Field Therapy

IMPACTED PLANS: Medicaid, HIV-SNP, and HARP

MPH_Provider_Banner

TO: All Providers

Effective 12/1/25, MetroPlusHealth will cover the provision of Tumor Treatment Field Therapy (TTFT) when billed under HCPCS code E0766 for the treatment of Glioblastoma Multiforme. TTFT is described as alternating electric fields generated by an external device placed on the patient’s head and delivered via ceramic transducers. These electric fields are designed to disrupt cancer cell division and inhibit tumor growth. MetroPlusHealth will cover this treatment per the DME Procedure Codes & Coverage Guidelines for our members, and it is billable once a month.

Please note prior authorization is required.

Coverage Criteria:

TTFT is covered only when all the following criteria are met:

  • The member is 22 years of age or older; and a. Confirmation of non-pregnant status for women of child-bearing age.
  • The member has received initial treatment with maximal debulking surgery, followed by chemotherapy and radiotherapy; and
  • Tumor treatment field therapy is initiated within 7 weeks from the last dose of concomitant chemotherapy or radiotherapy, whichever is later; and
  • The member has no evidence of progression by Response Assessment in Neuro-Oncology (RANO) criteria; and
  • The member will use tumor treatment field therapy (TTFT) for an average of 18 hours per day.

Important Notes:

  • Initial Prior Approval- If all criteria are met, TTFT will be approved for an initial 3‑month period.
  • TTFT will be denied as not reasonable and necessary for the treatment of recurrent glioblastoma multiforme (GBM).
  • Reimbursement for E0766 includes both the treatment device and all associated supplies for the duration of therapy

Continued Coverage:

To continue treatment beyond the initial 3 months:

  • Between Day 60 and Day 91 of therapy, the treating practitioner must complete a clinical reevaluation,
  • There must be documentation that the beneficiary is continuing to use and benefit from TTFT

For more details, please refer to the DME Procedure Code Manual, page 11 & 74: https://www.emedny.org/ProviderManuals/DME/PDFS/DME_Procedure_Codes.pdf

If you have any questions regarding this memo, please contact MetroPlusHealth at: [email protected].

> Download the PDF

 

last updated: February 27, 2026
MetroPlusHealth
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.